The novel coronavirus SARS-CoV-2 is the cause of COVID-19, a disease that has affected millions of people across the globe. As part of an Innovate UK funded project (No:58909), Pharmidex's In-Silico team have established a high-throughput screening capability for testing compounds against known structural proteins of SARS-CoV-2. As a result, we can generate 3D pharmacophore models to identify novel ligands and provide predictions of their ADMET properties.
Pharmidex is keen to collaborate with interested parties seeking to identify new medicines for COVID-19 using In-Silico directed strategies, either to identify protein targets that interact with clinically tested drugs, or screen compound libraries for potential hits at selected protein targets.
In addition, Pharmidex's Integrated Therapeutics Group have the necessary translational capabilities required to exploit any new drug targets efficiently and effectively.
